Tumor-infiltrating CD8+CXCR5+ T cells also highly express PD-1 and ICOS, which may indicate that blocking CD8+ T cell immune checkpoint inhibitors could serve as a therapeutic option in the future. The gene discussed is CD8A; the disease is neoplasm.